archive_header_en_20251203154432269.png

20230323085903895_en.png

app_icon.png

Change account information such as the email address and password on the account setting screen common to Confit.

Login required to view

Password required to view

Presentation Information

Session Details

Enter the password to view the abstracts.<br><br>The password will be emailed to those who have completed the registration.

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

Program Type

Sessions

Announcements

Profile management

Bookmark

Search presentations

Download PDF for print

Timetable

Development of theranostics probes targeting erythropoietin-producing hepatocellular A2 receptor expressed in cancer

As the saying goes, "Seeing is believing," information obtained by visualization is beneficial to identifying the location and size of lesions and evaluating the efficacy of treatment. In addition to its benefit in clinical settings, visualization of endogenous and exogenous molecules can lead to the elucidation of biological phenomena in the body and the optimization of treatment/diagnosis in basic and translational research. Various imaging modalities and technologies are used for visualization, and multimodal imaging has significantly contributed to the advancement of medical/pharmaceutical sciences. Imaging modalities or agents can also be applied to therapy directly or indirectly. This symposium will discuss the scientific significance of each imaging technique and address in what way each modality leads to therapy, in particular, frequently-used imaging modalities, "fluorescence," "ultrasound," "nuclear imaging," and "magnetic resonance imaging." As the theme of this symposium indicates, we would like as many meeting participants as possible to attend each presentation and recognize the amazingness of "imaging," knowing that "All imaging leads to therapy."

The Pharmaceutical Society of Japan

The 144th Annual Meeting of the Pharmaceutical Society of Japan (Yokohama)

The 144th Annual Meeting of the Pharmaceutical Society of Japan (Yokohama)

[S01-3]Development of theranostics probes targeting erythropoietin-producing hepatocellular A2 receptor expressed in cancer

Password required to view